Arbutus Biopharma CorporationABUSNASDAQ
LOADING
|||
Operating Income Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year operating income growth rate
Latest
-657.33%
↓ 706% below average
Average (39q)
-81.56%
Historical baseline
Range
High:104.29%
Low:-1256.73%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -657.33% |
| Q2 2025 | 104.29% |
| Q1 2025 | -148.75% |
| Q4 2024 | 35.01% |
| Q3 2024 | 0.66% |
| Q2 2024 | -11.47% |
| Q1 2024 | 6.67% |
| Q4 2023 | 3.76% |
| Q3 2023 | -17.26% |
| Q2 2023 | -5.58% |
| Q1 2023 | 22.82% |
| Q4 2022 | -26.67% |
| Q3 2022 | -26.24% |
| Q2 2022 | -28.57% |
| Q1 2022 | 47.23% |
| Q4 2021 | -12.97% |
| Q3 2021 | 1.26% |
| Q2 2021 | -18.92% |
| Q1 2021 | 3.83% |
| Q4 2020 | -7.12% |
| Q3 2020 | -15.80% |
| Q2 2020 | 0.05% |
| Q1 2020 | -0.86% |
| Q4 2019 | 85.74% |
| Q3 2019 | -345.53% |
| Q2 2019 | -7.57% |
| Q1 2019 | -12.83% |
| Q4 2018 | 47.87% |
| Q3 2018 | -47.08% |
| Q2 2018 | -19.78% |
| Q1 2018 | 69.45% |
| Q4 2017 | -367.16% |
| Q3 2017 | 33.81% |
| Q2 2017 | -6.48% |
| Q1 2017 | 92.89% |
| Q4 2016 | -1256.73% |
| Q3 2016 | 90.28% |
| Q2 2016 | -877.36% |
| Q1 2016 | -69.90% |
| Q4 2015 | 79.78% |